CR1 and hematocrit: The aim of our study was the selective downmodulation of autoreactive anti-Tg B lymphocytes from HT patients with an engineered protein molecule consisting of an anti-CR1 monoclonal antibody coupled to peptide epitopes derived from human Tg.